These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19795406)

  • 21. Recent advances in abzyme studies.
    Suzuki H
    J Biochem; 1994 Apr; 115(4):623-8. PubMed ID: 8089074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positional ordering of reacting groups contributes significantly to the efficiency of proton transfer at an antibody active site.
    Seebeck FP; Hilvert D
    J Am Chem Soc; 2005 Feb; 127(4):1307-12. PubMed ID: 15669871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models.
    Di Niro R; Ziller F; Florian F; Crovella S; Stebel M; Bestagno M; Burrone O; Bradbury AR; Secco P; Marzari R; Sblattero D
    BMC Biotechnol; 2007 Aug; 7():46. PubMed ID: 17678525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigations into the development of catalytic activity in anti-acetylcholinesterase idiotypic and anti-idiotypic antibodies.
    Johnson G; Moore SW
    J Mol Recognit; 2009; 22(3):188-96. PubMed ID: 19051205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Sports medicine: Mr Hyde and Dr.Jekyll! ].
    Gremion G; Fritschy D
    Rev Med Suisse; 2009 Aug; 5(212):1539-40. PubMed ID: 19728446
    [No Abstract]   [Full Text] [Related]  

  • 26. Computational tools for designing and engineering biocatalysts.
    Damborsky J; Brezovsky J
    Curr Opin Chem Biol; 2009 Feb; 13(1):26-34. PubMed ID: 19297237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Catalytic properties of IgMs with amylolytic activity isolated from patients with multiple sclerosis.
    Ivanen DR; Kulminskaya AA; Shabalin KA; Isaeva-Ivanova LV; Ershova NA; Saveliev AN; Nevinsky GA; Neustroev KN
    Med Sci Monit; 2004 Aug; 10(8):BR273-80. PubMed ID: 15277988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrabody construction and expression. II. A synthetic catalytic Fv fragment.
    Ohage EC; Wirtz P; Barnikow J; Steipe B
    J Mol Biol; 1999 Sep; 291(5):1129-34. PubMed ID: 10518948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyroid antibodies in spontaneous autoimmune thyroiditis in the Buffalo rat.
    Noble B; Yoshida T; Rose NR; Bigazzi PE
    J Immunol; 1976 Nov; 117(5 Pt 1):1447-55. PubMed ID: 794410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies.
    Ulrich HD; Schultz PG
    J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Catalytically active antibodies (abzymes) in human milk].
    Kit IuIa; Stoĭka RS
    Ukr Biokhim Zh (1999); 2007; 79(2):5-16. PubMed ID: 18030744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Phenomenon of DNA-abzyme cross-reactivity and its significance for the mechanisms of cytotoxicity and apoptosis].
    Suchkov SV; Gabibov AG; Gnuchev NV
    Ontogenez; 2001; 32(5):348-52. PubMed ID: 11605407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of complementary proteins in autoimmunity: an old idea re-emerges with new twists.
    McGuire KL; Holmes DS
    Trends Immunol; 2005 Jul; 26(7):367-72. PubMed ID: 15927527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression improvement and mechanistic study of the retro-Diels-Alderase catalytic antibody 10F11 by site-directed mutagenesis.
    Zheng L; Goddard JP; Baumann U; Reymond JL
    J Mol Biol; 2004 Aug; 341(3):807-14. PubMed ID: 15288788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Directed evolution governed by controlling the molecular recognition between an abzyme and its haptenic transition-state analog.
    Takahashi-Ando N; Kakinuma H; Fujii I; Nishi Y
    J Immunol Methods; 2004 Nov; 294(1-2):1-14. PubMed ID: 15604011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human catalytic RNA- and DNA-hydrolyzing antibodies.
    Nevinsky GA; Buneva VN
    J Immunol Methods; 2002 Nov; 269(1-2):235-49. PubMed ID: 12379364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The rapid discovery of engineered antibodies.
    Wang M; He M
    IDrugs; 2007 Aug; 10(8):562-5. PubMed ID: 17665332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies.
    Wootla B; Rao DN; Friboulet A; Uda T; Lacroix-Desmazes S; Kaveri SV
    Clin Rev Allergy Immunol; 2009 Oct; 37(2):97-104. PubMed ID: 19160072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Creation of catalytic antibodies metabolizing organophosphate compounds.
    Kurkova IN; Smirnov IV; Belogurov AA; Ponomarenko NA; Gabibov AG
    Biochemistry (Mosc); 2012 Oct; 77(10):1139-46. PubMed ID: 23157294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Exceptional Diversity of Catalytic Antibodies with Varying Activity in the Blood of Autoimmune and Viral Disease Patients].
    Buneva VN; Nevinsky GA
    Mol Biol (Mosk); 2017; 51(6):969-984. PubMed ID: 29271961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.